Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H46O |
| Molecular Weight | 386.6535 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
InChI
InChIKey=HVYWMOMLDIMFJA-DPAQBDIFSA-N
InChI=1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25,28H,6-8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1
| Molecular Formula | C27H46O |
| Molecular Weight | 386.6535 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/24616704Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28506805 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06d72b32-f4cc-4c8f-a449-91146bbc41e1
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24616704
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28506805 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06d72b32-f4cc-4c8f-a449-91146bbc41e1
Cholesterol is a sterol (a combination steroid and alcohol) and a lipid found in the cell membranes of all body tissues, and transported in the blood plasma of all animals. The high level of cholesterol in the blood is a marker of hypercholesterolemia, also called dyslipidemia. As a part of homeopathic product, it helps to support general liver and gallbladder health, and is used for temporary relief of symptoms related to adrenal glands such as fatigue and low energy. Cholesterol binds to and affects the gating of a number of ion channels such as the nicotinic acetylcholine receptor (nAChR) Inwardly-rectifying K+ channels (Kir); Transient receptor potential vanilloid 1 channels (TRPV1) and Large-conductance Ca2+-sensitive voltage-gated K+ channels (BK). It was shown the new mechanistic insights into the role of cholesterol in the regulation of nAChR, showing that cholesterol regulates the channels by two distinct mechanisms: stabilization of the channels in a resting state that depends on specific lipid-protein interactions and facilitation of the transitions between uncoupled and coupled states that depends on the hydrophobic thickness of the membrane
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17116000
Curator's Comment: a low synthesis of cholesterol is present in the brain, a mechanism for compensatory elimination is required. It was discovered, that favoured mechanism for this involves conversion into 24S-hydroxycholesterol, followed by diffusion over the blood-brain barrier
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P63252 Gene ID: 3759.0 Gene Symbol: KCNJ2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21559361/ |
|||
Target ID: Q8NER1 Gene ID: 7442.0 Gene Symbol: TRPV1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21555515/ |
|||
Target ID: CHEMBL2111384 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24013278/ |
|||
Target ID: CHEMBL3038495 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22474334/ |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
|||
| Diagnostic | Unknown Approved UseUnknown |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://www.jbc.org/content/286/21/18426.short Page: - |
yes [Ki 10 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://dmd.aspetjournals.org/content/34/4/513.short Page: - |
yes [Km 13.3 uM] | |||
Sources: https://dmd.aspetjournals.org/content/34/4/513.short Page: - |
yes [Km 3.4 uM] | |||
Sources: https://dmd.aspetjournals.org/content/34/4/513.short Page: - |
yes [Km 5.3 uM] | |||
Sources: https://dmd.aspetjournals.org/content/34/4/513.short Page: - |
yes [Km 7 uM] | |||
Page: - |
yes | |||
Sources: https://www.nature.com/articles/ncomms7354/ Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: - |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Preoperative lipid control with simvastatin reduces the risk for graft failure already 1 year after myocardial revascularization. | 2001-02 |
|
| Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). | 2001-01-06 |
|
| Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. | 2001-01-06 |
|
| Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. | 2001-01-03 |
|
| Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing. | 2001-01-03 |
|
| Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. | 2001-01-02 |
|
| Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. | 2001-01-02 |
|
| Women's Healthy Lifestyle Project: A randomized clinical trial: results at 54 months. | 2001-01-02 |
|
| Cracking down on caveolin: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in modulating edothelial cell nitric oxide production. | 2001-01-02 |
|
| Quantification of plasma membrane ergosterol of Saccharomyces cerevisiae by direct-injection atmospheric pressure chemical ionization/tandem mass spectrometry. | 2001-01-01 |
|
| High-density lipoprotein cholesterol and vascular stiffness at baseline in the activity counseling trial. | 2001-01-01 |
|
| Acute increases in plasma oxidized low-density lipoprotein immediately after percutaneous transluminal coronary angioplasty. | 2001-01-01 |
|
| Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. | 2001-01-01 |
|
| Pharmacological profile of F 12511, (S)-2',3', 5'-trimethyl-4'-hydroxy-alpha-dodecylthioacetanilide a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor. | 2001-01-01 |
|
| Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. | 2001-01-01 |
|
| Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1. | 2001-01 |
|
| Life-style factors and risk for abdominal aortic aneurysm in a cohort of Finnish male smokers. | 2001-01 |
|
| Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. | 2001-01 |
|
| Screening family members at high risk for coronary disease. Why isn't it done? | 2001-01 |
|
| Frequency of the R3500Q mutation of the apolipoprotein B-100 gene in a sample screened clinically for familial hypercholesterolemia in Hungary. | 2001-01 |
|
| Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. | 2001-01 |
|
| Plasma lipids and cardiovascular risk: a POSCH report. Program on the Surgical Control of the Hyperlipidemias. | 2001-01 |
|
| The effect of a garlic preparation on plasma lipid levels in moderately hypercholesterolemic adults. | 2001-01 |
|
| Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients. | 2001-01 |
|
| Impaired renal vascular endothelial function in vitro in experimental hypercholesterolemia. | 2001-01 |
|
| Essential role for the (hepatic) LDL receptor in macrophage apolipoprotein E-induced reduction in serum cholesterol levels and atherosclerosis. | 2001-01 |
|
| Raloxifene and estrogen reduces progression of advanced atherosclerosis--a study in ovariectomized, cholesterol-fed rabbits. | 2001-01 |
|
| Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. | 2001-01 |
|
| Gelatin intake increases the atheroma formation in apoE knock out mice. | 2001-01 |
|
| The LDL receptor is the major pathway for beta-VLDL uptake by mouse peritoneal macrophages. | 2001-01 |
|
| 17beta-estradiol, gender independently, reduces atheroma development but not neointimal proliferation after balloon injury in the rabbit aorta. | 2001-01 |
|
| Inability of plasma high-density lipoproteins to inhibit cell adhesion molecule expression in human coronary artery endothelial cells. | 2001-01 |
|
| The sialylation of plasma lipoproteins. | 2001-01 |
|
| Alcohol intake, type of beverage, and the risk of cerebral infarction in young women. | 2001-01 |
|
| Ask the doctor. I've been fighting obesity all my life. I'm a 62-year-old woman and every five years or so I lose about 20 pounds, then slowly gain it back. I've heard that this "yo-yo" pattern of weight loss, weight gain, weight loss, may be more dangerous than just staying heavy. Should I give up trying to lose weight? | 2001-01 |
|
| Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial. The British-Italian Gallstone Study group. | 2001-01 |
|
| PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. | 2001-01 |
|
| The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. | 2001-01 |
|
| Resolution of alcohols by cholesterol oxidase fromRrhodococcus erythropolis: lack of enantiospecificity for the steroids. | 2001-01 |
|
| Effect of lipid reduction on the progression of renal disease: a meta-analysis. | 2001-01 |
|
| Accumulation of cholesterol with age in human Bruch's membrane. | 2001-01 |
|
| Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. | 2001-01 |
|
| Role of meiosis-activating sterols in rat oocyte maturation: effects of specific inhibitors and changes in the expression of lanosterol 14alpha-demethylase during the preovulatory period. | 2001-01 |
|
| Dexamethasone inhibits luteinizing hormone-induced synthesis of steroidogenic acute regulatory protein in cultured rat preovulatory follicles. | 2001-01 |
|
| Meiosis-activating sterol and the maturation of isolated mouse oocytes. | 2001-01 |
|
| Body mass index and metabolic risk factors for coronary heart disease in women. | 2001-01 |
|
| Maternal hypercholesterolemia during pregnancy influences the later development of atherosclerosis: clinical and pathogenic implications. | 2001-01 |
|
| The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen. | 2001-01 |
|
| Oligonucleotides as inhibitors of protein synthesis. | 2001 |
|
| Eight novel LDL receptor gene mutations among patients under LDL apheresis in Dresden and Leipzig. | 2001 |
Sample Use Guides
fatigue: 1-10 drops under the tongue, 2 times a day or as directed by a health professional.
gallbladder health: Adults: Take five granules three times daily or as recommended by your healthcare practitioner. Children: Take three garnules and follow adult directions.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:55:00 GMT 2025
by
admin
on
Mon Mar 31 17:55:00 GMT 2025
|
| Record UNII |
97C5T2UQ7J
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LOINC |
47228-2
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
14440-2
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
90364-1
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
9618-0
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
12183-0
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
12773-8
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
91111-5
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
39469-2
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
43394-6
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
13459-3
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
69419-0
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
91118-0
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
2085-9
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
74433-4
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
34695-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
47220-9
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
32308-9
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
57936-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
48618-3
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
CFR |
21 CFR 862.1175
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
14443-6
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
14444-4
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
47213-4
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
56036-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
25371-6
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
51591-6
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
70201-9
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
35243-5
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
91110-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
43396-1
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
2565-0
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
70200-1
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
56135-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
IARC | Cholesterol | ||
|
LOINC |
2092-5
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
2096-6
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
16616-5
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
53135-0
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
CFR |
21 CFR 310.531
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
48620-9
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
91112-3
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
48637-3
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
2091-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
35200-5
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
35388-8
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
91116-4
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
2087-5
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
5932-9
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
9322-9
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
91105-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
9342-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
29765-5
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
54373-6
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
54372-8
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
50193-2
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
35199-9
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
55838-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
NCI_THESAURUS |
C68342
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
59250-1
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
66126-4
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
18262-6
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
32309-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
91107-3
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
47219-1
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
48635-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
18261-8
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
48090-5
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
35387-0
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
2093-3
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
14439-4
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
50192-4
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
55607-6
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
91115-6
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
39468-4
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
16615-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
91114-9
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
27340-9
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
59038-0
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
2090-9
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
12772-0
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
91106-5
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
9832-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
12771-2
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
50194-0
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
13458-5
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
56912-9
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
50840-8
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
CFR |
21 CFR 101.75
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
22748-8
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
11054-4
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
50409-2
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
43395-3
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
91117-2
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
26016-6
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
46986-6
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
47221-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
56133-2
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
54470-0
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
2095-8
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
13460-1
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
12531-0
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
91109-9
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
70202-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
14647-2
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
13457-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
35198-1
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
44915-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
44711-0
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
91113-1
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
14646-4
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
74435-9
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
DSLD |
195 (Number of products:6032)
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
47218-3
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
70204-3
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
56132-4
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
54469-2
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
70203-5
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
2089-1
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
57937-5
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
54467-6
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
49133-2
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
2094-1
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
26015-8
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
54371-0
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
9833-5
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
49624-0
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
91108-1
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
14155-6
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
49130-8
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
14442-8
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
14438-6
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
9830-1
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
56035-9
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
48089-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
50339-1
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
14441-0
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
35197-3
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
18263-4
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
48636-5
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
49132-4
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
2086-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
53133-5
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
26017-4
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
44733-4
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
53082-4
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
54468-4
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
2088-3
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
56134-0
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
78518-8
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
66499-5
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
54471-8
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
54438-7
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
||
|
LOINC |
55440-2
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
200-353-2
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | |||
|
7106
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | |||
|
16113
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | |||
|
CHOLESTEROL
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | |||
|
97C5T2UQ7J
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | |||
|
8798
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | |||
|
DB04540
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | |||
|
100000078528
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | |||
|
m3478
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | Merck Index | ||
|
57-88-5
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | |||
|
CHEMBL112570
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | |||
|
C369
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | |||
|
5997
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | |||
|
DTXSID3022401
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | |||
|
97C5T2UQ7J
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | |||
|
D002784
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | |||
|
SUB12480MIG
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | |||
|
1131960
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | |||
|
2438
Created by
admin on Mon Mar 31 17:55:00 GMT 2025 , Edited by admin on Mon Mar 31 17:55:00 GMT 2025
|
PRIMARY | RxNorm |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
CALENDULA OFFICINALIS FLOWER terpenoid
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
LABELED -> NON-LABELED |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
INHIBITOR OF ABSORPTION->TARGET |
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
INHIBITOR OF ABSORPTION->TARGET |
|
||
|
|
INHIBITOR OF ABSORPTION->TARGET |
|
||
|
|
INHIBITOR OF ABSORPTION->TARGET |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
In human brain
|
||
|
METABOLITE -> PARENT |
PREDOMINANTLY METABOLIZED IN MACROPHAGES
MAJOR
|
||
|
PARENT -> METABOLITE |
|
||
|
METABOLITE -> PARENT |
In steroidogenic tissues
|
||
|
|
METABOLITE -> PARENT |
25-HYDROXYCHOLESTEROL activates the ER-localized enzyme ACAT to induce internalization of accessible cholesterol on the plasma membrane and restricts SARS-CoV-2 S protein-mediated fusion which inhibits virus replication
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
ALLOSTERIC ACTIVATOR
|